MedTrace Logo

Cognitive Dysfunction After Cataract Surgery

NCT04730596 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-04-20

No results posted yet for this study

Summary

* Cataract surgery is commonly performed in elderly patients who are at high risk for developing postoperative cognitive dysfunction. Most cataract surgeries are performed under peribulbar or retrobulbar anesthesia, however, most of the patients require sedation to relieve the perioperative anxiety and induce amnesia. So, many sedative agents can be used especially benzodiazepines which may increase the risk of developing postoperative cognitive dysfunction.
* Ketamine can be used as a sedative and analgesic agent in a dose of 0.25 -0.5 mg/kg with certain studies suggesting that it may decrease the risk of postoperative cognitive dysfunction. Similarly, dexmedetomidine can be used as a sedative and analgesic agent with the possibility of decreasing the incidence of postoperative cognitive dysfunction.
* this controlled study will compare the effect of ketamine or dexmedetomidine on the POCD of patients undergoing cataract surgery.

Conditions

  • POCD - Postoperative Cognitive Dysfunction

Interventions

DRUG

Ketamine

Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.

DRUG

Dexmedetomidine

Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.

DRUG

Normal saline

Normal saline in a labeled syringe

Sponsors & Collaborators

  • Magrabi Hospital - Doha

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohamed Oreby, M.D · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-04-15
Completion
2021-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730596 on ClinicalTrials.gov